Drug resistance interpretation: IN	HIVDB	0B 9.5.1 (2023-11-05)
INSTI Major Mutations: INSTI Accessory Mutations: IN Other Mutations:	None E10D • L101I • G106A • K156N • V165I • S195C • V201I • I220V	
Integrase Strand Transfer Inhibitors		
bictegravir (BIC) cabotegravir (CAB) dolutegravir (DTG) elvitegravir (EVG) raltegravir (RAL)	Potential Low-Level Resistance Low-Level Resistance Potential Low-Level Resistance High-Level Resistance High-Level Resistance	
IN comments		
Major		
N155H is a common nonpolymorphic INSTI-resistance mutations. It has been reported in a high proportion of persons developing VF and HIVDR while receiving RAL, EVG, DTG, and CAB. Alone, it reduces RAL and EVG susceptibility about 10 and 30-fold, respectively. It has minimal effect on susceptibility to DTG, BIC, and CAB.		
This virus is predicted to have low-level reduced susceptibility to CAB. The use of the combination of CAB/RPV should be considered to be relatively contraindicated.		
Mutation scoring: IN	HIVDB	08 9.5.1 (2023-11-05)
Drug resistance mutation scores of INSTI	Ti: Download CSV	